Pardo B - Search Results

1

Phase I and pharmacokinetic study of trabectedin 3-hour infusion every three weeks in patients with advanced cancer and alteration of hepatic function.

Pardo B, Salazar R, Ciruelos E, Cortés-Funes H, García M, Majem M, Montes A, Cuadra C, Soto-Matos A, Lebedinsky C, Alfaro V, Paz-Ares L. Pardo B, et al. Med Oncol. 2012 Sep;29(3):2240-50. doi: 10.1007/s12032-011-9979-8. Epub 2011 Jun 10. Med Oncol. 2012. PMID: 21660618 Clinical Trial.

2

Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors.

Pardo B, Paz-Ares L, Tabernero J, Ciruelos E, García M, Salazar R, López A, Blanco M, Nieto A, Jimeno J, Izquierdo MA, Trigo JM. Pardo B, et al. Clin Cancer Res. 2008 Feb 15;14(4):1116-23. doi: 10.1158/1078-0432.CCR-07-4366. Clin Cancer Res. 2008. PMID: 18281545 Clinical Trial.

3

A phase I clinical and pharmacokinetic study (LIPOTEC - GP PHARM/DOXO 01) of a new liposomal doxorubicin given as 3-week schedule in patients with solid tumors.

Majem M, Salazar R, Garcia M, Clopes A, Muñoz C, Pardo B, Martinez M, Cuadra C, Montes A, Mis R, Savulsky C, Ramon Germa-Lluch J. Majem M, et al. Among authors: pardo b. J Liposome Res. 2009;19(4):261-6. doi: 10.3109/08982100902804833. J Liposome Res. 2009. PMID: 19863161 Clinical Trial.

4

Phase I study of weekly plitidepsin as 1-hour infusion combined with carboplatin in patients with advanced solid tumors or lymphomas.

Salazar R, Plummer R, Oaknin A, Robinson A, Pardo B, Soto-Matos A, Yovine A, Szyldergemajn S, Calvert AH. Salazar R, et al. Among authors: pardo b. Invest New Drugs. 2011 Dec;29(6):1406-13. doi: 10.1007/s10637-010-9488-1. Epub 2010 Jul 10. Invest New Drugs. 2011. PMID: 20623160 Clinical Trial.

5

Phase I study of weekly kahalalide F as prolonged infusion in patients with advanced solid tumors.

Salazar R, Cortés-Funes H, Casado E, Pardo B, López-Martín A, Cuadra C, Tabernero J, Coronado C, García M, Soto Matos-Pita A, Miguel-Lillo B, Cullell-Young M, Iglesias Dios JL, Paz-Ares L. Salazar R, et al. Among authors: pardo b. Cancer Chemother Pharmacol. 2013 Jul;72(1):75-83. doi: 10.1007/s00280-013-2170-5. Epub 2013 May 5. Cancer Chemother Pharmacol. 2013. PMID: 23645288 Clinical Trial.

6

Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.

Izquierdo MA, Bowman A, García M, Jodrell D, Martinez M, Pardo B, Gómez J, López-Martin JA, Jimeno J, Germá JR, Smyth JF. Izquierdo MA, et al. Among authors: pardo b. Clin Cancer Res. 2008 May 15;14(10):3105-12. doi: 10.1158/1078-0432.CCR-07-1652. Clin Cancer Res. 2008. PMID: 18483378 Clinical Trial.

7

Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors.

Vidal L, Magem M, Barlow C, Pardo B, Florez A, Montes A, Garcia M, Judson I, Lebedinsky C, Kaye SB, Salazar R. Vidal L, et al. Among authors: pardo b. Invest New Drugs. 2012 Apr;30(2):616-28. doi: 10.1007/s10637-010-9559-3. Epub 2010 Oct 7. Invest New Drugs. 2012. PMID: 20927639 Clinical Trial.

8

Fungal infections in patients with solid tumors treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation.

Montesinos J, Sola C, Maroto P, Salazar R, Balmaña J, Ramírez A, Pardo B, Pericás R, Gurgui M, López-López JJ. Montesinos J, et al. Among authors: pardo b. Eur J Clin Microbiol Infect Dis. 2001 Aug;20(8):569-72. doi: 10.1007/s100960100555. Eur J Clin Microbiol Infect Dis. 2001. PMID: 11681437

9

Volasertib Versus Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: A Randomized Phase II Groupe des Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire Study.

Pujade-Lauraine E, Selle F, Weber B, Ray-Coquard IL, Vergote I, Sufliarsky J, Del Campo JM, Lortholary A, Lesoin A, Follana P, Freyer G, Pardo B, Vidal L, Tholander B, Gladieff L, Sassi M, Garin-Chesa P, Nazabadioko S, Marzin K, Pilz K, Joly F. Pujade-Lauraine E, et al. Among authors: pardo b. J Clin Oncol. 2016 Mar 1;34(7):706-13. doi: 10.1200/JCO.2015.62.1474. Epub 2016 Jan 11. J Clin Oncol. 2016. PMID: 26755507 Clinical Trial.

10

Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients.

Rodriguez-Freixinos V, Fariñas-Madrid L, Gil-Martin M, Barretina-Ginesta P, Romeo M, Villacampa G, Pardo B, Ahmed H, Recalde S, Piulats JM, Gómez-Plaza MC, Gil-Moreno A, Sala E, Martínez-Román S, Ponce J, Meléndez C, Carballas E, Dienstmann R, Oaknin A. Rodriguez-Freixinos V, et al. Among authors: pardo b. Gynecol Oncol. 2019 Feb;152(2):270-277. doi: 10.1016/j.ygyno.2018.11.036. Epub 2018 Dec 12. Gynecol Oncol. 2019. PMID: 30551885

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

232 results

Search Page

Filters